Database / Tirzepatide
Tirzepatide
Zepbound / Mounjaro · Eli Lilly. The strongest approved option on weight and the gentlest on the stomach of any drug with full Phase 3 data. Acts on two gut hormones, GLP-1 and GIP.
Average weight loss
22.5%
Stopped for side effects
6.2%
Trial length
72 wk
Ranking score
8.8
SURMOUNT-1 results
Phase 3 · 72 weeks · 15 mg weekly
Adults with obesity, no diabetes (n=2,539)
Weight loss
22.5%
Nausea
31.0%
Vomiting
12.2%
Diarrhea
23.0%
Constipation
11.7%
Quit due to side effects
6.2%
n/r = not reported. Counting everyone who started, weight loss was 20.9%. Placebo group: 3.1%.
Worth knowing
- Head-to-head SURMOUNT-5 trial beat semaglutide on weight loss.
- Also approved for obstructive sleep apnea in adults with obesity.
8.8
GLP-1 Performance Index
Rank 1 of 6 ranked drugs
Stomach = (31.0 + 12.2 + 23.0 + 11.7) ÷ 4
= 19.5
Burden = 19.5 + 1 × 6.2 = 25.7
Index = 22.5 ÷ 25.7 × 10 = 8.76
At a glance
- Company
- Eli Lilly
- Targets
- GLP-1, GIP
- Molecule
- Peptide
- Dosing
- Injection, weekly
- Status
- FDA approved (Nov 2023)